Navigation Links
ARCA Discovery Announces Data Demonstrating Potential for Bucindolol as Targeted Therapy in Heart Failure, Atrial Fibrillation, and Ventricular Arrhythmia
Date:11/6/2007

during the trial that examined the effects of bucindolol in beta-1 adrenergic receptor gene variants (beta-1 389 Arg/Arg and Gly carriers).

In the adrenergic receptor genetic substudy, chronic administration of bucindolol resulted in a significant reduction in cardiovascular hospitalizations and mortality. Effects on both were strikingly beta-1 389 Arg/Gly specific, with the higher functioning, Arg/Arg version of the receptor associated with large treatment effects (compared to placebo, reduction in time to event CV hospitalizations by 34% (p = 0.003), CV hospitalizations/patient by 35% (p = 0.005), number of days CV hospitalized/patient by 36% (p = 0.005), and cardiovascular mortality by 46% (p = 0.015)). The presentation concluded that genetic targeting of the beta-1 AR 389 polymorphism may improve the clinical responses to bucindolol for CV mortality and morbidity.

"Effect of b1 389 Arg/Gly a2c 322-325 Wt/Del Genotypes on Adjudicated Hospitalizations in the BEST Trial" (Presentation #2912) presented, in an oral presentation by Dr. Peter Carson of the Virginia Medical Center, data from a recent adjudication by the BEST nine member endpoints committee (EPC), in which they reviewed all 5,086 hospitalizations from the study, recognized by the FDA as an important endpoint in evaluating heart failure drugs.

The analysis revealed that the EPC method -- due to its level of specificity -- adjudicated fewer hospitalizations due to worsening heart failure as compared to the investigator/CRF method. In addition, the EPC adjudication tended to increase effect size, although the CRF method of identifying heart failure hospitalizations yielded similar qualitative results.

The results presented by Dr. Carson demonstrated both the beta-1 389 Arg/Arg adrenergic receptor polymorphism and the alpha-2c wild type gene variant are positively correlated with certain major clinical responses to bucindolol (all-cause mortality, cardiovascular mortality and days eac
'/>"/>

SOURCE ARCA Discovery, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
2. New Company Starts, Bridging the Development Gap in the Discovery of Cancer Drugs
3. Trana Discovery and Southern Research Institute Announce the First RNA-RNA High Throughput Drug Screening Assay Platform for HIV Antivirals
4. ActiveSight and CHDI Leverage Fragment-Based Lead Discovery for Huntington Disease Therapies
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
9. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
10. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
11. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... 31, 2014 STAAR Surgical Company (NASDAQ: ... of implantable lenses and delivery systems for the eye ... 4, 2014 of $20.0 million, a 10% increase over ... On a constant currency basis, revenues grew 11% during ... quarter of 2013.  The effect of foreign currency exchange ...
(Date:7/31/2014)... Inc. (NYSE: RMD ) today announced results for ... 30, 2014.  Revenue for the quarter was $415.2 million, flat ... percent decrease on a constant currency basis). Net income was ... quarter ended June 30, 2013. Diluted earnings per share for ... to the quarter ended June 30, 2013.  ...
(Date:7/31/2014)... 31, 2014 Xencor Inc. (NASDAQ: ... engineered monoclonal antibodies for the treatment of autoimmune ... reported financial results for the second quarter ended June ... business highlights. "In the second quarter, ... Society 2014 International Conference (ATS) demonstrating three novel ...
Breaking Medicine Technology:STAAR Surgical Reports 10% Second Quarter Revenue Growth 2STAAR Surgical Reports 10% Second Quarter Revenue Growth 3STAAR Surgical Reports 10% Second Quarter Revenue Growth 4STAAR Surgical Reports 10% Second Quarter Revenue Growth 5STAAR Surgical Reports 10% Second Quarter Revenue Growth 6STAAR Surgical Reports 10% Second Quarter Revenue Growth 7STAAR Surgical Reports 10% Second Quarter Revenue Growth 8STAAR Surgical Reports 10% Second Quarter Revenue Growth 9STAAR Surgical Reports 10% Second Quarter Revenue Growth 10STAAR Surgical Reports 10% Second Quarter Revenue Growth 11STAAR Surgical Reports 10% Second Quarter Revenue Growth 12STAAR Surgical Reports 10% Second Quarter Revenue Growth 13STAAR Surgical Reports 10% Second Quarter Revenue Growth 14STAAR Surgical Reports 10% Second Quarter Revenue Growth 15STAAR Surgical Reports 10% Second Quarter Revenue Growth 16STAAR Surgical Reports 10% Second Quarter Revenue Growth 17STAAR Surgical Reports 10% Second Quarter Revenue Growth 18STAAR Surgical Reports 10% Second Quarter Revenue Growth 19STAAR Surgical Reports 10% Second Quarter Revenue Growth 20STAAR Surgical Reports 10% Second Quarter Revenue Growth 21STAAR Surgical Reports 10% Second Quarter Revenue Growth 22STAAR Surgical Reports 10% Second Quarter Revenue Growth 23STAAR Surgical Reports 10% Second Quarter Revenue Growth 24STAAR Surgical Reports 10% Second Quarter Revenue Growth 25STAAR Surgical Reports 10% Second Quarter Revenue Growth 26STAAR Surgical Reports 10% Second Quarter Revenue Growth 27STAAR Surgical Reports 10% Second Quarter Revenue Growth 28STAAR Surgical Reports 10% Second Quarter Revenue Growth 29STAAR Surgical Reports 10% Second Quarter Revenue Growth 30STAAR Surgical Reports 10% Second Quarter Revenue Growth 31RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 2RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 3RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 4RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 5RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 6
... Oncomine and Oncomine Concepts Map Integral in Expression and Association ... ... Building on an earlier study,that used Oncomine(TM) to identify ETS-fusion proteins ... identification of,four additional classes of ETS rearrangements in prostate cancer, each of,which ...
... ... Annually, CAMBRIDGE, Mass., Aug. 2 ... trial of Mozobil(TM),(plerixafor) has successfully met its primary and secondary endpoints,demonstrating positive ... non-Hodgkin,s lymphoma. The combined strength of these two trials -- in ...
Cached Medicine Technology:Gene Fusion Subtypes in Prostate Carcinoma Have Clinical Implications 2Genzyme Announces Second Pivotal Mozobil Trial Meets Primary Endpoint 2Genzyme Announces Second Pivotal Mozobil Trial Meets Primary Endpoint 3Genzyme Announces Second Pivotal Mozobil Trial Meets Primary Endpoint 4Genzyme Announces Second Pivotal Mozobil Trial Meets Primary Endpoint 5Genzyme Announces Second Pivotal Mozobil Trial Meets Primary Endpoint 6Genzyme Announces Second Pivotal Mozobil Trial Meets Primary Endpoint 7
(Date:8/1/2014)... 01, 2014 On Monday, June 30th, ... User Symposium in San Francisco, CA. Now in its ... JW Marriott Union Square hotel. , “We are excited ... to speed with ACA compliance issues,” Quirk Healthcare Foundation ... symposium provides attendees guidance with NextGen implementation and use, ...
(Date:8/1/2014)... Alan Mozes HealthDay Reporter ... country, barbershops serve as a time-honored destination for a good ... whether barbershops might also be the spot to tackle an ... In a novel partnership, the U.S. Centers for Disease ... Health (MSDH), enlisted the help of barbershop staff to both ...
(Date:8/1/2014)... The North America Endpoint Security Market report defines and ... with analysis and forecast of revenue. This market is ... to $4.77 billion by 2019, at a CAGR of ... TOC of the North America Endpoint Security Market report ... It also provides a glimpse of the segmentation in ...
(Date:8/1/2014)... 1, 2014 The Cardiovascular Research Foundation (CRF) ... investigations that will be presented at next month,s ... the world,s premier educational meeting specializing in interventional ... 17, 2014 at the Walter E. Washington Convention ... presented at TCT often direct the course of ...
(Date:8/1/2014)... NY (PRWEB) August 01, 2014 ... The company develops biomarkers. Its products include CytoSure ... ISCA +SNP Array, CytoSure ISCA UPD array, CytoSure ... v2 array. OGT offers services, such as targeted ... RNA-Seq service, miRNA analysis, gene expression analysis, cytosure ...
Breaking Medicine News(10 mins):Health News:Quirk Healthcare Foundation Hosts Fifth Annual California NextGen User Symposium and Launches First Annual Florida NextGen User Symposium 2Health News:Barbershops Join Fight Against High Blood Pressure in Black Men 2Health News:Barbershops Join Fight Against High Blood Pressure in Black Men 3Health News:North America End-Point Security Market is Expected to Reach $4 billion in 2019 - New Report by MicroMarket Monitor 2Health News:North America End-Point Security Market is Expected to Reach $4 billion in 2019 - New Report by MicroMarket Monitor 3Health News:North America End-Point Security Market is Expected to Reach $4 billion in 2019 - New Report by MicroMarket Monitor 4Health News:CRF announces late-breaking trials and first report investigations for TCT 2014 2Health News:CRF announces late-breaking trials and first report investigations for TCT 2014 3Health News:CRF announces late-breaking trials and first report investigations for TCT 2014 4Health News:Oxford Gene Technology Market Size, Share, Analysis, Trends and Forecasts 2014 2Health News:Oxford Gene Technology Market Size, Share, Analysis, Trends and Forecasts 2014 3
... SALAAM, Tanzania, April 25 Today is a,great day for ... and a day to,celebrate. We celebrate because of the possibilities ... today by the United,Nations Secretary General His Excellency Ban Ki-Moon, ... initiative is implemented to the,letter, millions of lives will be ...
... Inc. (NYSE:,NTY) (http://www.NBTY.com ), a leading global manufacturer ... web cast the,presentation by Harvey Kamil, President and Chief ... And Restaurant Conference in,New York on Tuesday, April 29, ... cast live on the Company Web,site, http://www.nbty.com ...
... (Nasdaq: THOR ), a world leader in ... restore failing hearts,today announced that it will report ... 2008 on Thursday, May 1., The company ... financial,results and operating activities to all interested parties ...
... and who,s telling the truth , , FRIDAY, April 25 ... window into the soul, but scientists have been reporting ... imperceptible facial expressions -- tell the real story of ... that people have a lot more trouble hiding their ...
... and reduced risk of recurrence during tuberculosis chemotherapy, according ... of The Journal of Infectious Diseases, now available online. ... common before the advent of anti-TB drugs, is no ... low-income countries even though poor nutrition impairs the immune ...
... Inc.,(Nasdaq: SMBL ) will hold its annual meeting ... 2008, at the Teaneck Marriott at Glenpointe, 100,Frank W. ... the close of business on April 2, 2008, are ... come before the meeting., About Smart Balance Inc., ...
Cached Medicine News:Health News:Statement by H.E. Jakaya Mrisho Kikwete, President of the United Republic of Tanzania, and Chairman of the African Union, in Response to UN-SG Call to Action on Malaria 2Health News:NBTY to Webcast Presentation at Lehman Brothers 11th Annual Retail and Restaurant Conference 2Health News:Thoratec Schedules First Quarter 2008 Conference Call, Webcast 2Health News:Fleeting Facial Expressions Reveal Deep Secrets 2Health News:Fleeting Facial Expressions Reveal Deep Secrets 3Health News:Study shows common vitamin and other micronutrient supplements reduce risks of TB recurrence 2
... For Excellent Drainage PLUS Greater Patient ... BLAKE Drains are white, radiopaque silicone drains ... a solid core center. Their other components ... extension tubing and an adapter. The drains ...
Used for percutaneous placement of laparoscopic surgical instruments. Check-Flo® valve provides a secure seal around the instruments to be introduced. Supplied sterile in peel-open packages. Inte...
Used for internal biliary drainage. Supplied sterile in peel-open packages. Intended for one-time use....
Used for common bile duct exploration. Supplied sterile in peel-open packages. Intended for one-time use....
Medicine Products: